Q2 FY2026 EarningsQ2 FY26 results missed consensus across all bottom-line metrics as the company transitions to a commercial skincare stage. Revenue of $0 was in-line with expectations, while Net Loss of $2.97M was 34% wider than the expected $2.21M. EPS of -$0.74 missed the -$0.55 consensus by $0.19, driven by a sharp 142% YoY increase in SG&A expenses related to the upcoming launch of Tome™ Foundational Treatment on August 25, 2026. Cash runway is guided into Q4 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Dermata Therapeutics(DRMA) the EBIT is -3.014 M (-69.97%), Miss estimate;the EPS is -0.74 (+55.42%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.00B69.97%
-0.00B28.48%
-0.00B41.49%
EPSMiss expectations
-0.7455.42%
-0.5566.87%
-0.190011.45%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf